Daya CNS is a private biopharmaceutical company headquartered in Saint Peters, Missouri. The company's product pipeline comprises non-opioid treatments and novel antipsychotic drugs designed with fewer side effects.
Subscribe to see Daya CNS, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Daya CNS, LLC is a therapeutics company headquartered in Saint Louis, United States. Its most recent funding round raised $228,310 in August 2015. Xcout tracks 5 named people at Daya CNS, LLC, including Terence Stern (Chief Financial Officer).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $228,310 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Daya CNS, LLC's closest competitors — see the full list of competitors and alternatives →
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders. Its pipeline focuses on treating conditions such as suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder. The company utilizes a proprietary NMDA platform for its therapeutic developments.
Psylo, Inc. is a biotechnology company focused on the discovery and development of next-generation neuroplastogens to treat psychiatric and neurological conditions. The company leverages medicinal chemistry and pharmacology to engineer safer, non-hallucinogenic psychedelic-inspired therapeutics. Its research and drug development efforts primarily serve patients suffering from treatment-resistant mental health disorders.
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Cajal Neuroscience (Cajal Therapeutics Inc.) is a biotechnology company headquartered in Seattle, Washington. The company is dedicated to advancing therapeutic pipelines in neuroscience research.
BlackThorn Therapeutics is a biotechnology company developing treatments for neuropsychiatric and neurological disorders, using computational biology, neuroscience, and clinical data to support drug discovery and development. Its work is aimed at patients with conditions such as depression and other disorders involving brain circuitry and behavior.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Daya CNS, LLC? Suggest a correction · Work at Daya CNS, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.